BIBLIOGRAPHY / LINKS
Acharya SA, Intaglietta M, Tsai AG, Malavalli A, Vandegriff K, Winslow RM, Smith PK, Friedman JM, and Manjula BN. Enhanced molecular volume of conservatively PEGYlated Hb: (SP-PEG5K)6-HbA is non-hypertensive. Art Cells, Blood Subs, & Immob Biotech, 33: 239-255, 2005.
Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, and Winslow RM. A Phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica, 90(4):505-15, 2005.
Cabrales P, Tsai AG, Winslow RM, and Intaglietta M. Effects of extreme hemodilution with hemoglobin based O2 carriers on microvascular pressure. Am J Physiol Heart Circ Physiol, 288(5):H2146-53, 2005.
Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol Heart Circ Physiol, 289: 2392-2400, 2005.
Drobin D, Kjellstrom BT, Malm E, Malavalli A, Lohman J, Vandegriff KD, Young MA, and Winslow RM. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol, 96:1843-1853, 2004.
Intaglietta M, Johnson P and Winslow RM. Microvascular and tissue oxygen distribution. Cardiovascular Research, 32: 632-643, 1996.
Intaglietta M, Winslow RM. Artificial blood. In: Bronzino, J., (ed.), Tissue Engineering and Artificial Organs. Taylor & Francis. Hartford, 2006, pp 74: 1-16.
Kerger H, Tsai A, Saltzman J, Winslow RM and Intaglietta M. Fluid resuscitation with O2 vs. non-O2 carriers after 2h of hemorrhagic shock in conscious hamsters. Am J Physiol, 272: H525-H537, 1997.
Manjula B, Tsai A, Upadhya R, Perumalsamy K, Smith P, Malavalli A, Vandegriff K, Winslow R, Intaglietta M, Prabhakaran M, Friedman J and Acharya A. Site-specific PEGylation of hemoglobin at Cys-93 (beta): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem, 14(2): 464-472, 2003.
McCarthy R, Vandegriff D and Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobin: Implications for the design of hemoglobin-based oxygen carriers. Biophys Chem, 92: 103-117, 2001.
Olofsson, Christina; Ahl, Torbjörn; Johansson, Torsten; Larsson, Sune; Nellgård, Per; Ponzer, Sari; Fagrell, Bengt; Przybelski, Robert; Keipert, Peter; Winslow, Nancy; Winslow, RM. A multi-center clinical study of the safety and activity of maleimide-polyethylene glycol-hemoglobin (Hemospan®) in patients undergoing major orthopedic surgery. Anesthesiology, 105(6): 1153 – 1163, 2006.
Stowell C, Levin J, Spiess B and Winslow RM. Progress in the development of RBC substitutes. Transfusion, 41: 287-299, 2001.
Tsai A, Cabrales P, Winslow RM and Intaglietta M. Microvascular oxygen distribution in awake hamster window chamber model during hyperoxia. Am J Physiol Heart Circ Physiol, 285: H1537-H1545, 2003.
Tsai A, Vandegriff K, Intaglietta M and Winslow R. Targeted O2 delivery by cell-free hemoglobin: A new basis for oxygen therapeutics. Am J Physiol, 285: H1411-H1419, 2003.
Tsai AG, Cabrales P, Acharya S, Manjula BN, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood, Jul 20, 2006 (e-publication).
Vandegriff K, Malavalli A, Wooldridge J, Lohman J and Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion, 43: 509-516, 2003.
Vandegriff KD, Bellelli A, Brunori M, Samaja M, Malavalli A, and Winslow RM. Kinetics of NO and O2 binding to a high O2 affinity hemoglobin, modified by surface conjugation to maleimide-activated PEG that does not show a pressor effect. Biochem J, 382(pt 1):183-9, 2004.
Vandegriff KD, Malavalli A, Minn C, Jiang E, Lohman J, Young MA, Samaja M, and Winslow RM. Oxidation and heme loss kinetics of polyethylene glycol-conjugated hemoglobin (MP4): Dissociation between in vitro and in vivo oxidation rates. Biochem J, 463-467, 2006.
Wettstein R, Cabrales P, Erni D, Tsai A, Winslow RM, Intaglietta M. Resuscitation from hemorrhagic shock with MalPeg-Albumin: comparison with MalPeg-Hemoglobin. Shock, 22(4):351-7, 2004.
Winslow R. Oxygen transport agents: a new approach to red blood cell alternatives. Transfusion Alternatives in Transfusion Medicine, 5(6): 498-504, 2004.
Winslow RM, Intaglietta M, Tsai A, Vandegriff K, and Wettstein R. Autoregulation and vasoconstriction: Foundation for a new generation of blood substitutes. Blood, 100(11), 210. 11-16-2002.
Winslow RM, Keipert P, Winslow N, Olofsson N, Fagrell B, Ahl T, Johansson T, Larsson S, Nellgard P, Ponzer S, Przybelski R. A multi-center study of the safety and efficacy of MP4 (Hemospan®) in orthopedic surgery patients. Crit Care Med, 33(12) (supplement, A6), 2006.
Winslow RM, Lohman J, Malavalli A, Vandegriff K. A comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol, 97(4):212-4, 2004.
Winslow RM. Current status of oxygen carriers (“blood substitutes”): 2006. Vox Sang, 91(2): 102-105, 2006.
Winslow RM. Hemospan: scientific foundations and clinical development. ISBT Science Series, 1(1):161-166, 2006.
Winslow RM. Blood Substitutes. In: Anderson, KC and Ness, PM (eds.), Blood Banking and Transfusion Medicine, 2nd Edition. Philadelphia: W.B. Saunders, pp. 588-598, 2006.
Winslow RM. Blood Substitutes. London: Elsevier Inc., 2005
Winslow RM. The role of p50 in tissue oxygen delivery by cell-free oxygen carriers. In Kobayashi,K, Tsuchida, E. and Horinouchi, H. (eds.) Artificial Oxygen Carrier: Its Front Line. Keio University International Symposia for Life Sciences and Medicine Vol.12, pp. 38-52, Springer-Verlag, Tokyo, 2005.
Winslow RM. Targeted O2 delivery by low-p50 hemoglobin: a new basis for hemoglobin-based oxygen carriers. Art Cells, Blood Subs & Biotech, 33(1):1-12, 2005.
Winslow RM. MP4, a new non-vasoactive polyethylene glycol-hemoglobin conjugate. Art Orgs J, 28(9):800-6, 2004.
Winslow RM. Alternative oxygen therapeutics: products, status of clinical trials, and future prospects. Curr Hematol Rep, 2(6): 503-510, 2003.
Winslow RM. Current status of blood substitute research: Toward a new paradigm. Journal of Internal Medicine, 253: 508-517, 2003.
Winslow RM. Maleimide-polyethylene glycol modified human hemoglobin. Crit Care Med, 31(12): 2815-2816, 2003.
Winslow RM. Current status of red cell substitutes ("Oxygen Therapeutics") In: Emerging Diagnostic and Therapeutic Technologies in Transfusion Medicine, edited by Stowell C and Dzik W. Bethesda, MD: AABB Press, 2003.
Winslow RM. Blood Substitutes. In: Kirk-Othmer Encyclopedia of Chemical Technology, New York, NY: John Wiley & Sons, Inc., 2003.
Winslow RM. Blood Substitutes. Curr Opin Hematol, 9: 146-151, 2002.
Winslow RM. αα- Crosslinked Hemoglobin: Was failure predicted by preclinical testing? Vox Sang, 79 (1): 1-20, 2000.
Young M, Riddez L, Kjellström T, Bursell J, Winslow F, Lohman J, Winslow RM. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med, 33(8): 1794-1804, 2005.